Supplementary Data — Regdanvimab reduced COVID-19 risk: real-time meta-analysis of 12 studies

@CovidAnalysis, October 2026, Version 11V11 (V1 2023)
c19early.org
October 2026

Regdanvimab COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Lee59%0.41 · 0.02–10.06death0/2341/544 Lee (PSM)82%0.18 · 0.06–0.52severe case234 (n)234 (n) Lee (PSM)45%0.55 · 0.30–1.00oxygen234 (n)234 (n) Lee8%0.92 · 0.87–0.97no disch.234 (n)544 (n) Lee77%0.23 · 0.09–0.58no disch.5/23450/544 Streinu-.. (DB RCT)−151%2.51 · 0.10–61.14ventilation1/2030/104 Streinu-.. (DB RCT)54%0.46 · 0.18–1.15oxygen8/2039/104 Streinu-.. (DB RCT)49%0.51 · 0.21–1.25hosp.9/2039/104 Streinu-.. (DB RCT)49%0.51 · 0.21–1.25progression9/2039/104 Streinu-.. (DB RCT)35%0.65 · 0.49–0.86recov. time203 (n)104 (n) Streinu-.. (DB RCT)2%0.98 · 0.81–1.20viral time203 (n)104 (n) Chae71%0.29 · 0.01–5.76death0/252/99 Chae64%0.36 · 0.05–2.66ventilation1/2511/99 Chae9%0.91 · 0.68–1.23hosp. time25 (n)99 (n) Park (PSM)79%0.21 · 0.12–0.34progression19/37781/377 Park (PSM)13%0.87 · 0.83–0.91hosp. time377 (n)377 (n) Jang60%0.40 · 0.26–0.63oxygen17/7379/137 Jang44%0.56 · 0.33–0.94no disch.14/7347/137 Jang35%0.65 · 0.50–0.85no disch.34/7398/137 Jang13%0.87 · 0.79–0.96hosp. time73 (n)137 (n) Kim (DB RCT)50%0.50 · 0.05–5.53death1/6562/659 Kim (DB RCT)86%0.14 · 0.01–2.77ventilation0/6563/659 Kim (DB RCT)91%0.09 · 0.01–1.64ICU0/6565/659 Kim (DB RCT)69%0.31 · 0.17–0.54oxygen15/65649/659 Kim (DB RCT)69%0.31 · 0.18–0.54hosp.16/65652/659 Kim (DB RCT)70%0.30 · 0.18–0.52progression16/65653/659 Kim (DB RCT)72%0.28 · 0.16–0.51progression14/44648/434 Kim (DB RCT)32%0.68 · 0.60–0.77viral+612 (n)618 (n) Jang70%0.30 · 0.01–7.25death0/4181/304 Jang12%0.88 · 0.84–0.92hosp. time418 (n)304 (n) Jang49%0.51 · 0.41–0.64oxygen92/418130/304 Jang68%0.32 · 0.22–0.48no disch.31/41870/304 Kim51%0.49 · 0.34–0.71progression1,095 (n)1,119 (n) Kim34%0.67 · 0.35–1.27progression1,095 (n)1,119 (n) Kim32%0.68 · 0.56–0.82oxygen1,095 (n)1,119 (n) Kim4%0.96 · 0.70–1.33oxygen1,095 (n)1,119 (n) Fomina−415%5.15 · 1.46–18.23viral+7/243/53OT1 Hwang83%0.17 · 0.02–1.37death1/1896/189 Hwang92%0.08 · 0.00–1.36death0/1896/189 Hwang0%1.00 · 0.06–15.87ventilation1/1891/189 Hwang33%0.67 · 0.28–1.59ICU8/18912/189 Hwang55%0.45 · 0.25–0.82oxygen14/18931/189 Lee59%0.41 · 0.22–0.76death10/7749/153 Choi86%0.14 · 0.01–2.56death0/655/333 Choi76%0.24 · 0.07–0.60oxygen4/6567/333
00.511.52+
1 OT: comparison with other treatment
Rotate screen for more detailsIncrease width for more details
← Regdanvimab
reduces riskRegdanvimab
increases risk →
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.